Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet

Shares of Entrada Therapeutics, Inc. (TRDA) have gained 17% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 37.1%. The average comprises three short-term price targets ranging from a low of $18 to a high of $25, with a standard deviation of $3.61. While the lowest estimate i ...